Beth Hecht - See Remarks, Xeris Biopharma Holdings, Inc
As of January 5, 2022
Beth Hecht Net Worth
- Net worth is estimated to be at least $1.04M
- Owns at least 57,083 units of Xeris Biopharma Holdings, Inc stock
Beth Hecht Compensation at Xeris Biopharma Holdings, Inc in 2020
- Earned a $392,852 salary
- Rewarded $286,650 in stock value and options
- Received a total compensation of $1,244,394
Beth Hecht Trading
- Largest purchase of shares was 2,500 units , worth over $25K on February 22, 2019
- In total has made about 13 transactions over 3 years
- Usually trades in February, with the busiest year in 2020
Beth Hecht
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
Beth Hecht Mailing Address
- Mailing address is C/o Neos Therapeutics, Inc. 2940 N. Highway 360 Grand Prairie TX 75050 TX
Xeris Biopharma Holdings, Inc Executive Compensation
Name |
Year
|
Salary
|
Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
---|---|---|---|---|---|---|---|
Paul Edick, | 2020 | $626,977 | $1,178,450 | $ | $453,222 | $5,700 | $2,264,349 |
Paul Edick, | 2019 | $598,277 | $1,735,000 | $1,598,580 | $370,181 | $5,600 | $4,307,638 |
John Shannon, | 2020 | $473,658 | $414,050 | $246,300 | $300,000 | $2,420 | $1,436,428 |
John Shannon, | 2019 | $444,479 | $ | $639,432 | $178,500 | $5,171 | $1,267,582 |
Beth Hecht, | 2020 | $392,852 | $286,650 | $369,450 | $189,808 | $5,634 | $1,244,394 |
Beth Hecht, | 2019 | $364,417 | $ | $259,769 | $145,782 | $5,600 | $775,568 |
No matching records found |
Source: https://www.sec.gov/Archives/edgar/data/1346302/000134630221000036/a2021proxystatement.htm
Xeris Biopharma Holdings, Inc Insider Trading
- The most recent transaction was 100,000 units bought on May 13, 2022 by Paul Edick worth over $140.38K
- In the last 4 years, insiders at Xeris Biopharma Holdings, Inc sold an estimated value of $3.18M and bought an estimated value of $31.3M
- The most active traders are Steven Prestrelski, Chief Scientific Officer, Paul Edick, See Remarks, and Patrick John Shannon Jr, See Remarks
- Insider trading is most common in October, with the busiest year in 2021
Xeris Biopharma Holdings, Inc. Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |